The use of the FXR agonist BAR502 can significantly reduce the insulin resistance of non-alcoholic steatohepatitis model mice, thereby promoting white fat browning and reversing liver steatosis (35). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.